Extraordinary meeting of the Committee for Medicinal Products for Human Use (CHMP): 19 November 2021
EventHumanCOVID-19Vaccines
Date
- Friday, 19 November 2021
Location
- OnlineEuropean Medicines Agency, Amsterdam, the Netherlands
This extraordinary plenary meeting is organised in the context of the Article 5(3) reviews of COVID-19 treatments Lagevrio (molnupiravir) and Paxlovid (PF-07321332 / ritonavir).
The Committee for Medicinal Products for Human Use (CHMP) is responsible for preparing the European Medicines Agency's opinions on all questions concerning human medicines.